[Chinese expert consensus on the management of corneal and ocular surface adverse events related to antibody-drug conjugates (2026)].

Antibody-drug conjugates (ADCs), as a novel class of targeted anticancer therapies, have demonstrated significantly enhanced efficacy. However, the associated ocular adverse events have emerged as a critical issue impacting patients' quality of life and treatment compliance. ADC-induced ocular adverse events primarily affect corneal and ocular surface tissues. With the recent approval of multiple ADC agents in China and the extensive ongoing clinical trials, standardized guidance for managing corneal and ocular surface adverse events is urgently needed. The Dry Eye Research Group of Ophthalmology Branch of Chinese National Health Association and the Dry Eye Rehabilitation Specialty of Vision Rehabilitation Committee of Chinese Rehabilitation Medicine Association, together with experts from relevant fields, have developed consensus recommendations based on integrated international research and Chinese clinical practice, using the standardized consensus development methods. These recommendations address eight clinical questions concerning corneal and ocular surface adverse events associated with ADCs, aiming to provide evidence-based guidance for the prevention, diagnosis, and management of ADC-related corneal and ocular surface adverse events. Through multidisciplinary collaboration, this consensus seeks to enhance therapeutic benefits of ADC treatment and maximize patients' visual health and quality of life.